Developer docs
API playgroundTry for free, no card

Search company profiles

ImmunoPhotonics

Full company profile

uuid0000hni

Namestring
ImmunoPhotonics
Legal namestring
Immunophotonics, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ImmunoPhotonics is a privately held, clinical-stage biotechnology company pioneering a therapeutic category it has trademarked as Interventional Immuno-Oncology (IIO). The company's lead and only disclosed product is IP-001 (also referenced as inCVAX), a proprietary cationic glycan polymer designed to be injected at the site of routine tumor ablation procedures (RFA, MWA, cryoablation) or radiation. IP-001 functions as both an antigen depot—capturing tumor antigens liberated during ablation—and an immune activator that recruits antigen-presenting cells, engages the cGAS-STING innate immune pathway, and drives downstream T-cell activation while downregulating T-cell exhaustion. The intent is to convert a local, mechanical tumor-destruction procedure into a systemic immunotherapy capable of reaching distant metastases.

The company targets six solid tumor indications: colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma, soft tissue sarcoma (STS), hepatocellular carcinoma (HCC), and pancreatic cancer. It has completed the SAKK 66/17 Phase 1b/2a trial in collaboration with the Swiss Cancer Institute and the INJECTABL-1 Phase 1b/2a trial across the US, UK, France, Germany, and Switzerland, treating more than 120 patients cumulatively. A pivotal INJECTABL-3 Phase 2/3 trial is being conducted in partnership with CIRSE. IP-001 is also being explored as a vaccine adjuvant for infectious diseases, extending the platform's vertical scope beyond oncology.

The business model is currently pre-revenue. ImmunoPhotonics has no commercial product sales and no disclosed pricing; IP-001 is administered exclusively through clinical trials. Revenue mechanics are not yet established but are expected to flow through traditional pharmaceutical distribution channels, specialty pharmacies, and potentially licensing or co-development partnerships for global commercialization upon regulatory approval. The company has raised approximately $31.8 million in equity and grant financing since 2010, including a $21.4 million round in April 2022. Operations are based in St. Louis, Missouri (headquarters) and Bern, Switzerland (subsidiary IPS Biopharma AG), with patent coverage in over 40 countries and European exclusivity extending into 2039.

Short descriptiontext

ImmunoPhotonics is a privately held, clinical-stage biotech developing IP-001, a proprietary glycan polymer immunotherapy injected after tumor ablation to convert local procedures into systemic cancer immunotherapy, targeting multiple solid tumor indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Cancer immunotherapy, Interventional oncology, Solid tumor treatment, Glycan polymer therapeutics, Tumor ablation immunotherapy
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy / Interventional Immuno-Oncology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/ Biopharmaceutical Sales (Future)
TypeOne Time License
Description

As a clinical-stage biotech company, Immunophotonics currently has no revenue. The company is developing IP-001 for cancer treatment, which if approved would be commercialized through traditional pharmaceutical distribution channels. The company may pursue licensing agreements or co-development partnerships for global commercialization.

immunophotonics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ImmunoPhotonics is a clinical-stage biopharmaceutical company developing IP-001 (inCVAX), a proprietary cationic glycan polymer immunotherapy administered as an intratumoral injection following routine tumor ablation (RFA, MWA, cryoablation) or radiation. IP-001 captures tumor antigens released during ablation and activates innate and adaptive immunity via the cGAS-STING pathway, transforming local procedures into systemic cancer immunotherapy across multiple solid tumor indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • IP-001 has been tested in over 120 patients across multiple solid tumor indications
+3 more records
Product overview1 text field

Immunophotonics is a clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology® with a single lead product, IP-001 (also referred to as inCVAX). IP-001 is a proprietary glycan polymer designed to stimulate the immune system by acting as an antigen depot and immune activator. The product is injected following routine tumor ablation procedures (such as RFA, MWA, or cryoablation) to capture tumor antigens released during ablation and activate antigen-presenting cells, thereby transforming local tumor destruction into a systemically active cancer immunotherapy. The company is also exploring IP-001 as a vaccine adjuvant for infectious diseases. The technology platform supports expansion into multiple solid tumor indications including colorectal cancer, NSCLC, melanoma, soft tissue sarcoma, hepatocellular carcinoma, and pancreatic cancer.

Product and service1 record
1IP-001 (inCVAX)
CategoryCancer Immunotherapy / Interventional Immuno-Oncology drug candidate
Description

Proprietary cationic glycan polymer administered as an intratumoral injection following standard tumor ablation (RFA, MWA, cryoablation) or radiation. Acts as an antigen depot and immune activator that captures liberated tumor antigens and stimulates innate and adaptive immunity via the cGAS-STING and inflammasome pathways, upregulating T-cell activation and downregulating T-cell exhaustion. Investigational; intended for solid tumor indications (colorectal, NSCLC, melanoma, soft tissue sarcoma, hepatocellular, pancreatic) with additional exploration as a vaccine adjuvant for infectious diseases.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Partnership for INJECTABL-3 Phase 2/3 clinical trial. CIRSE is a leading organization in interventional radiology, providing clinical trial support and physician network access for the innovative trial combining IP-001 with ablation procedures.

2Next Research
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Clinical research organization partner for INJECTABL-3 Phase 2/3 clinical trial, providing operational support for the innovative interventional immuno-oncology study.

immunophotonics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-14
Description

Research collaboration combining Immunophotonics' proprietary drug IP-001 with CLS's TRANBERG Laser Thermal Therapy System and imILT Method for cancer treatment. The collaboration supports Phase 1b/2a clinical trials combining IP-001 injection with laser ablation for solid tumor treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on SAKK 66/17 Phase 1b/2a multicenter clinical trial for treatment of solid tumors. Trial completed in 2025, evaluating IP-001 injection following thermal ablation in patients with advanced solid tumors including melanoma and soft tissue sarcoma.

5IPS Biopharma AG (Subsidiary)
Strategic tierCoreTypeOthers
Description

Swiss subsidiary headquartered in Bern, Switzerland, managing international business development, European clinical operations, and partnerships for Immunophotonics.

immunophotonics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Compugen uses computational biology to discover novel immuno-oncology targets, with COM701 (anti-PVRIG) in clinical development for solid tumors. It represents an emerging-platform competitor in the IO combination space.

TypeBroad incumbent
Description

BioNTech's mRNA cancer vaccine pipeline (BNT122, individualized neoantigen therapies) and FixVac platform target similar solid tumor indications and use immune activation approaches. While BioNTech is a much larger incumbent, both companies are racing to develop antigen-driven cancer immunotherapies.

TypeEmerging player
Description

Galectin develops galectin-3 inhibitors that modulate the tumor immune microenvironment and have shown activity in combination with checkpoint inhibitors. The platform approach of reprogramming immune response in solid tumors is similar in spirit to IP-001's mechanism.

TypeDirect peer
Description

Nektar developed novel cytokine-based immunotherapies (bempegaldesleukin) and agonistic antibodies designed to enhance T-cell activation in the tumor microenvironment. Its IL-10 and T-cell engagers are mechanistically aligned with IP-001's approach of boosting cytotoxic T-cell responses.

TypeEmerging player
Description

Werewolf develops tumor-activated immunotherapies (PREDATOR platform) that are designed to be activated selectively in the tumor microenvironment, sharing with IP-001 the goal of localizing immune activation at the tumor site while minimizing systemic toxicity.

TypeBroad incumbent
Description

Moderna's oncology mRNA programs (mRNA-4157/V940 individualized neoantigen therapy, checkpoint inhibitor combinations) directly compete in the personalized cancer vaccine space. Moderna's resources, manufacturing scale, and melanoma Phase 2b readout against Merck's Keytruda represent the most formidable competitive threat in the field.

TypeDirect peer
Description

Iovance develops autologous cell therapies (TIL) for solid tumors, directly competing for the same patient populations ImmunoPhotonics targets (melanoma, NSCLC, CRC). Both companies are in the post-ablation/standard-of-care solid tumor immunotherapy space with clinical-stage assets and large market opportunities.

TypeDirect peer
Description

ImmunityBio develops IL-15-based immunotherapies (ANKTIVA) and NK cell therapies for solid tumors. The company's focus on T-cell and NK-cell activation in combination with checkpoint inhibitors is mechanistically aligned with IP-001's Th-1 and cytotoxic T-cell activation profile.

9OncoSec Medical (now Via Bio)
TypeDirect peer
Description

OncoSec is a direct peer developing intratumoral immunotherapies (TAVO) that combine with tumor ablation/electroporation to generate systemic immune responses. Robert H. Arch, current President of ImmunoPhotonics, previously led strategy at OncoSec with TAVO-EP and FDA engagement, making the platforms and approaches highly comparable.

TypeOthers
Description

CLS is an existing co-development partner of ImmunoPhotonics, providing the TRANBERG laser ablation system used in the INJECTABL trials. As a strategic collaborator in the IIO combination workflow, CLS is an adjacent ecosystem participant enabling IP-001's clinical development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmunoPhotonics

Cancer Immunotherapy / Interventional Immuno-Oncologyimmunophotonics.com

ImmunoPhotonics is a privately held, clinical-stage biotech developing IP-001, a proprietary glycan polymer immunotherapy injected after tumor ablation to convert local procedures into systemic cancer immunotherapy, targeting multiple solid tumor indications.

What ImmunoPhotonics does

ImmunoPhotonics is a privately held, clinical-stage biotechnology company pioneering a therapeutic category it has trademarked as Interventional Immuno-Oncology (IIO). The company's lead and only disclosed product is IP-001 (also referenced as inCVAX), a proprietary cationic glycan polymer designed to be injected at the site of routine tumor ablation procedures (RFA, MWA, cryoablation) or radiation. IP-001 functions as both an antigen depot—capturing tumor antigens liberated during ablation—and an immune activator that recruits antigen-presenting cells, engages the cGAS-STING innate immune pathway, and drives downstream T-cell activation while downregulating T-cell exhaustion. The intent is to convert a local, mechanical tumor-destruction procedure into a systemic immunotherapy capable of reaching distant metastases.

The company targets six solid tumor indications: colorectal cancer (CRC), non-small cell lung cancer (NSCLC), melanoma, soft tissue sarcoma (STS), hepatocellular carcinoma (HCC), and pancreatic cancer. It has completed the SAKK 66/17 Phase 1b/2a trial in collaboration with the Swiss Cancer Institute and the INJECTABL-1 Phase 1b/2a trial across the US, UK, France, Germany, and Switzerland, treating more than 120 patients cumulatively. A pivotal INJECTABL-3 Phase 2/3 trial is being conducted in partnership with CIRSE. IP-001 is also being explored as a vaccine adjuvant for infectious diseases, extending the platform's vertical scope beyond oncology.

The business model is currently pre-revenue. ImmunoPhotonics has no commercial product sales and no disclosed pricing; IP-001 is administered exclusively through clinical trials. Revenue mechanics are not yet established but are expected to flow through traditional pharmaceutical distribution channels, specialty pharmacies, and potentially licensing or co-development partnerships for global commercialization upon regulatory approval. The company has raised approximately $31.8 million in equity and grant financing since 2010, including a $21.4 million round in April 2022. Operations are based in St. Louis, Missouri (headquarters) and Bern, Switzerland (subsidiary IPS Biopharma AG), with patent coverage in over 40 countries and European exclusivity extending into 2039.

ImmunoPhotonics firmographics

Firmographics
Name
ImmunoPhotonics
Legal name
Immunophotonics, Inc.
Website
https://immunophotonics.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
ImmunoPhotonics is a privately held, clinical-stage biotech developing IP-001, a proprietary glycan polymer immunotherapy injected after tumor ablation to convert local procedures into systemic cancer immunotherapy, targeting multiple solid tumor indications.
Ownership category
akta.pro rank

ImmunoPhotonics industry classification

Industry
Product category
Cancer Immunotherapy / Interventional Immuno-Oncology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAABAF
Dendritic Cell & Other APC-based Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Cancer immunotherapy
  • Interventional oncology
  • Solid tumor treatment
  • Glycan polymer therapeutics
  • Tumor ablation immunotherapy

Where ImmunoPhotonics is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ImmunoPhotonics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Pharmaceutical/ Biopharmaceutical Sales (Future): As a clinical-stage biotech company, Immunophotonics currently has no revenue. The company is developing IP-001 for cancer treatment, which if approved would be commercialized through traditional pharmaceutical distribution channels. The company may pursue licensing agreements or co-development partnerships for global commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

ImmunoPhotonics product offering

Product offering

Core offering

ImmunoPhotonics is a clinical-stage biopharmaceutical company developing IP-001 (inCVAX), a proprietary cationic glycan polymer immunotherapy administered as an intratumoral injection following routine tumor ablation (RFA, MWA, cryoablation) or radiation. IP-001 captures tumor antigens released during ablation and activates innate and adaptive immunity via the cGAS-STING pathway, transforming local procedures into systemic cancer immunotherapy across multiple solid tumor indications.

Product overview

Immunophotonics is a clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology® with a single lead product, IP-001 (also referred to as inCVAX). IP-001 is a proprietary glycan polymer designed to stimulate the immune system by acting as an antigen depot and immune activator. The product is injected following routine tumor ablation procedures (such as RFA, MWA, or cryoablation) to capture tumor antigens released during ablation and activate antigen-presenting cells, thereby transforming local tumor destruction into a systemically active cancer immunotherapy. The company is also exploring IP-001 as a vaccine adjuvant for infectious diseases. The technology platform supports expansion into multiple solid tumor indications including colorectal cancer, NSCLC, melanoma, soft tissue sarcoma, hepatocellular carcinoma, and pancreatic cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • IP-001 (inCVAX) Proprietary cationic glycan polymer administered as an intratumoral injection following standard tumor ablation (RFA, MWA, cryoablation) or radiation. Acts as an antigen depot and immune activator that captures liberated tumor antigens and stimulates innate and adaptive immunity via the cGAS-STING and inflammasome pathways, upregulating T-cell activation and downregulating T-cell exhaustion. Investigational; intended for solid tumor indications (colorectal, NSCLC, melanoma, soft tissue sarcoma, hepatocellular, pancreatic) with additional exploration as a vaccine adjuvant for infectious diseases.

Quantifiable outcome

  • IP-001 has been tested in over 120 patients across multiple solid tumor indications
  • +3 more outcomes

Companies that use ImmunoPhotonics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

ImmunoPhotonics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ImmunoPhotonics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • CIRSE (Cardiovascular and Interventional Radiological Society of Europe)coreStrategic or Co-development Partner · 1 September 2024Partnership for INJECTABL-3 Phase 2/3 clinical trial. CIRSE is a leading organization in interventional radiology, providing clinical trial support and physician network access for the innovative trial combining IP-001 with ablation procedures.
  • Next ResearchminorStrategic or Co-development Partner · 1 September 2024Clinical research organization partner for INJECTABL-3 Phase 2/3 clinical trial, providing operational support for the innovative interventional immuno-oncology study.
  • Clinical Laserthermia Systems (CLS)coreStrategic or Co-development Partner · 14 June 2019Research collaboration combining Immunophotonics' proprietary drug IP-001 with CLS's TRANBERG Laser Thermal Therapy System and imILT Method for cancer treatment. The collaboration supports Phase 1b/2a clinical trials combining IP-001 injection with laser ablation for solid tumor treatment.
  • Swiss Cancer InstitutecoreStrategic or Co-development PartnerCollaboration on SAKK 66/17 Phase 1b/2a multicenter clinical trial for treatment of solid tumors. Trial completed in 2025, evaluating IP-001 injection following thermal ablation in patients with advanced solid tumors including melanoma and soft tissue sarcoma.
  • IPS Biopharma AG (Subsidiary)coreOthersSwiss subsidiary headquartered in Bern, Switzerland, managing international business development, European clinical operations, and partnerships for Immunophotonics.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

ImmunoPhotonics competitors and assessment

Company assessment

Emerging players

  • Compugen: Compugen uses computational biology to discover novel immuno-oncology targets, with COM701 (anti-PVRIG) in clinical development for solid tumors. It represents an emerging-platform competitor in the IO combination space.
  • Galectin Therapeutics: Galectin develops galectin-3 inhibitors that modulate the tumor immune microenvironment and have shown activity in combination with checkpoint inhibitors. The platform approach of reprogramming immune response in solid tumors is similar in spirit to IP-001's mechanism.
  • Werewolf Therapeutics: Werewolf develops tumor-activated immunotherapies (PREDATOR platform) that are designed to be activated selectively in the tumor microenvironment, sharing with IP-001 the goal of localizing immune activation at the tumor site while minimizing systemic toxicity.

Broad incumbents

  • BioNTech: BioNTech's mRNA cancer vaccine pipeline (BNT122, individualized neoantigen therapies) and FixVac platform target similar solid tumor indications and use immune activation approaches. While BioNTech is a much larger incumbent, both companies are racing to develop antigen-driven cancer immunotherapies.
  • Moderna: Moderna's oncology mRNA programs (mRNA-4157/V940 individualized neoantigen therapy, checkpoint inhibitor combinations) directly compete in the personalized cancer vaccine space. Moderna's resources, manufacturing scale, and melanoma Phase 2b readout against Merck's Keytruda represent the most formidable competitive threat in the field.

Direct peers

  • Nektar Therapeutics: Nektar developed novel cytokine-based immunotherapies (bempegaldesleukin) and agonistic antibodies designed to enhance T-cell activation in the tumor microenvironment. Its IL-10 and T-cell engagers are mechanistically aligned with IP-001's approach of boosting cytotoxic T-cell responses.
  • Iovance Biotherapeutics: Iovance develops autologous cell therapies (TIL) for solid tumors, directly competing for the same patient populations ImmunoPhotonics targets (melanoma, NSCLC, CRC). Both companies are in the post-ablation/standard-of-care solid tumor immunotherapy space with clinical-stage assets and large market opportunities.
  • ImmunityBio: ImmunityBio develops IL-15-based immunotherapies (ANKTIVA) and NK cell therapies for solid tumors. The company's focus on T-cell and NK-cell activation in combination with checkpoint inhibitors is mechanistically aligned with IP-001's Th-1 and cytotoxic T-cell activation profile.
  • OncoSec Medical (now Via Bio): OncoSec is a direct peer developing intratumoral immunotherapies (TAVO) that combine with tumor ablation/electroporation to generate systemic immune responses. Robert H. Arch, current President of ImmunoPhotonics, previously led strategy at OncoSec with TAVO-EP and FDA engagement, making the platforms and approaches highly comparable.

Others

  • Clinical Laserthermia Systems (CLS): CLS is an existing co-development partner of ImmunoPhotonics, providing the TRANBERG laser ablation system used in the INJECTABL trials. As a strategic collaborator in the IIO combination workflow, CLS is an adjacent ecosystem participant enabling IP-001's clinical development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

ImmunoPhotonics social profiles

Digital presence

ImmunoPhotonics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmunoPhotonics leadership team

Management profile

Number of profiles

Profiles11 records

ImmunoPhotonics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ImmunoPhotonics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmunoPhotonics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmunoPhotonics

What does ImmunoPhotonics do?

ImmunoPhotonics is a clinical-stage biopharmaceutical company developing IP-001 (inCVAX), a proprietary cationic glycan polymer immunotherapy administered as an intratumoral injection following routine tumor ablation (RFA, MWA, cryoablation) or radiation. IP-001 captures tumor antigens released during ablation and activates innate and adaptive immunity via the cGAS-STING pathway, transforming local procedures into systemic cancer immunotherapy across multiple solid tumor indications.

Is ImmunoPhotonics a public or private company?

ImmunoPhotonics is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImmunoPhotonics founded?

ImmunoPhotonics was founded in 2011. It employs 11 to 50 people.

Where is ImmunoPhotonics based?

ImmunoPhotonics is headquartered in St Louis, United States, in the North America region.

How does ImmunoPhotonics make money?

One revenue line is on record: pharmaceutical/ Biopharmaceutical Sales (Future).

Who are ImmunoPhotonics's main competitors?

Emerging players on record are Compugen, Galectin Therapeutics and Werewolf Therapeutics. Broad incumbents are BioNTech and Moderna. Direct peers are Nektar Therapeutics, Iovance Biotherapeutics, ImmunityBio and OncoSec Medical (now Via Bio). Clinical Laserthermia Systems (CLS) is listed as an others.

Does ImmunoPhotonics have an API?

No public API is recorded for ImmunoPhotonics.

What industry is ImmunoPhotonics in?

ImmunoPhotonics's product category is Cancer Immunotherapy / Interventional Immuno-Oncology. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BizblipBiotech Startup Closes $10 Million Round, Names New CEOImmunophotonics closed a $10 million Series C round and promoted Robert H. Arch to president and CEO. The funding provides a two-year runway for clinical trials, with the company having raised about $41.5 million total. The lead investor was not disclosed.EIN PresswireImmunophotonics Secures Initial $10 Million Series C Financing and Appoints Robert H. Arch, Ph.D., as President and CEOImmunophotonics closed $10 million in Series C financing and appointed Robert Arch as CEO, effective September 1, 2026. The funds will support IP-001 clinical development and Phase 2 programs. Miguel Zubizarreta will remain on the board.PR NewswireSoft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsightDelveInsight published a market research report projecting the soft tissue sarcoma with lung metastases treatment market across the 7 major markets (US, EU4, UK, Japan) to grow steadily during the 2026–2036 forecast period, driven by anticipated launches of novel therapies. The report identifies several drug candidates in development including Annamycin (Moleculin), IP-001 (Immunophotonics), Fibromun (Philogen), Lifileucel (Iovance Biotherapeutics), and Chiauranib (Chipscreen). The US held the largest market share in 2025, with approximately 14,000 new soft tissue sarcoma cases diagnosed annually and up to 50% of patients eventually developing lung metastases.EIN PresswireData from Immunophotonics Phase 1b/2a Clinical Trial to Be Presented at ASCO 2026Immunophotonics will present data from its Phase 1b/2a trial of IP-001 at ASCO 2026 on May 30. The trial evaluated intratumoral IP-001 after thermal ablation in advanced melanoma and soft tissue sarcoma, finding it well tolerated with mainly mild, transient immune-related events. The company plans further clinical development to establish proof-of-concept.EIN PresswireImmunophotonics Secures European Patent Protecting Use of Lead Asset in Combination with Checkpoint InhibitorsImmunophotonics has secured a European patent protecting the use of its lead asset, IP-001, in combination with checkpoint inhibitors for treating solid tumors. This patent, validated in over 20 European countries, further strengthens the company's intellectual property position and supports ongoing clinical development. The patent highlights the potential of IP-001 to enhance anti-tumor immune responses when used with checkpoint inhibitors.EIN PresswireImmunophotonics Appoints Richard M. Levenson, M.D. to Board of DirectorsImmunophotonics, Inc., a clinical-stage biotech company developing IP-001 for interventional immuno-oncology, has appointed Richard M. Levenson, M.D. to its Board of Directors. Dr. Levenson brings over 40 years of experience in medical research, pathology, and advanced imaging technologies, including contributions to multispectral imaging and microscopy systems now being commercialized, and is expected to guide the company's strategic direction and support its growth. The appointment reflects Immunophotonics' ongoing effort to attract experienced leaders as it advances its cancer therapy pipeline through multiple clinical trials.SalesTech StarImmunophotonics Appoints Richard M. Levenson, M.D. to Board of DirectorsImmunophotonics, Inc., a clinical-stage biotech company developing immune-stimulating drugs for cancer therapy, has appointed Richard M. Levenson, M.D. to its Board of Directors. Dr. Levenson brings over 40 years of experience in medical research, pathology, and advanced imaging technologies, currently serving as Professor at UC Davis Medical Center, and is expected to guide the company's strategic direction and pipeline advancement. The appointment underscores the company's ongoing effort to attract experienced leadership as it works to advance its novel approach of converting local tumor destruction treatments into systemic immuno-therapies.PR NewswireImmunophotonics and Swiss Cancer Institute Complete SAKK 66/17 Phase 1b/2a Multicenter Clinical Trial for Treatment of Solid TumorsImmunophotonics, Inc. announced the completion of its multicenter clinical trial SAKK 66/17 in collaboration with the Swiss Cancer Institute, evaluating the safety and tolerability of IP-001 in combination with thermal ablation for patients with advanced solid tumors, with a second phase assessing efficacy for melanoma and soft-tissue sarcoma. All patients have completed treatment in both phases and data analysis is now underway. This milestone follows the completion of the company's INJECTABL-1 trial announced in July 2025, representing a significant advancement in the development of a potential new cancer treatment approach.